Krystal Biotech

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Earnings data Q1 2024

Krystal Biotech reports robust Q3 performance and plans for growth

Krystal Biotech's Q3 earnings call showcased strong financial performance, high patient conversion rates, and global expansion plans. While facing challenges related to patient adherence and reimbursement, the company is well-positioned for future growth and aims to capitalize on opportunities in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

The heavy selling pressure might have exhausted for Krystal Biotech (KRYS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround

• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707, a modified HSV-1 vector designed to deliver genes encoding both human interleukin-12 (IL-12) and interleukin-2 (IL-2) to the lung, for the treatment of patients with locally advanced or metastatic solid tumors of the lung. “Cytokine therapy holds significant potential for the treatment of solid tumors but its utility has been limited by a lack of safe and effective delivery options,” said David Chien, M.D.

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable

Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why

Alpine Immune Sciences

Gyre Therapeutics Inc

Neurocrine Biosciences

Vericel

The top five biotech stocks today have several commonalities. Among them are strong ratings.

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

Axsome Therapeutics

Catalyst Pharmaceuticals

Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Frequency Therapeutics Inc

Mereo Biopharma Group Plc - ADR

Takeda Pharmaceutical

Wave Life Sciences

Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why

Krystal Biotech, Inc. (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?

Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock

Viking Therapeutics

These two mid-cap biotechs have exciting pipelines. Important breakthroughs could lead to market-beating returns.

2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years

PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 44th Annual Health Care Conference, which takes place in Boston on March 4-6.

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Krystal Biotech, Inc. (KRYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why Momentum in Krystal Biotech, Inc. (KRYS) Should Keep going

Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.52 per share. This compares to loss of $1.25 per share a year ago.

Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates

•  Net product revenue of $42.1M in 4Q and $50.7M for the year •  New England Journal of Medicine publication of the use of B-VEC eyedrop formulation •  Reached alignment with FDA to enable approval of B-VEC eyedrop formulation for the treatment of lesions in the eye of DEB patients •  First patient dosed in Phase 1 KB408 trial for the treatment of AATD; five active clinical trials in 2024 •  Strong balance sheet, closing the year with $594.1M in cash and investments PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financial results on Monday, February 26, 2024, prior to the open of U.S. markets. Subsequently, at 8:30 am ET, the Company will host a webcast to discuss the financial results and provide a business update.

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for inhaled KB707 for the treatment of patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard of care therapy. “The lung is often the predominant site of metastasis for many different cancers, most of which have limited or no standard of care immunotherapy treatment options” said Daniel Johnson, MD, Director of the Center for Innovative Cancer Therapies at the Ochsner MD Anderson Cancer Center Medical Center in New Orleans, LA.

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal's HSV-1 platform to treat ocular diseases

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim 6th Annual Biotechnology Conference, which takes place in New York on February 7-8.

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J3401) for VYJUVEK® (beremagene geperpavec-svdt), the first U.S. Food and Drug Administration-approved treatment for dystrophic epidermolysis bullosa (DEB). The J-code for VYJUVEK became effective on January 1, 2024.

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

Krystal Biotech, Inc. (KRYS) Moves to Buy: Rationale Behind the Upgrade

PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to beremagene geperpavec-svdt (B-VEC or VYJUVEK) for the treatment of dystrophic epidermolysis bullosa (DEB).

News for Krystal Biotech Stock (KRYS)